Key Stats for Mirum Pharmaceuticals Stock
- Price change for Mirum Pharmaceuticals stock in the last 1 month: -20%
- $MIRM Stock Price as of Aug. 10: $99
- 52-Week High: $130
- $MIRM Stock Price Target: $138
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Mirum Pharmaceuticals (MIRM) stock is under pressure after the rare disease drugmaker reported a wider quarterly loss than a year ago, even as revenue and full-year guidance both moved higher.
- The company posted a loss of $0.80 per share for Q2, missing the $0.75 loss analysts expected and marking a significant step down from the $0.12 per share loss reported in the same quarter last year.
- Revenue told a much stronger story. Net product sales hit $176 million, up from $127.79 million a year ago and beating consensus estimates by nearly 7%.
- That growth came from strong demand for LIVMARLI, which brought in $129 million during the quarter, along with the company’s bile acid medicines, which contributed $48 million.
- Based on that momentum, Mirum raised its full-year 2026 net product sales guidance to a range of $680 million to $700 million.
The wider loss largely reflects heavier investment. Total operating expenses for the quarter reached $219 million, including a $16 million charge tied to licensing a new drug candidate called zilurgisertib, along with $76 million in R&D spending as the company pushes several pipeline programs toward key milestones.
Mirum also strengthened its balance sheet during the quarter, issuing $690 million in convertible notes and ending the period with $561 million in cash, cash equivalents, and investments, up sharply from $391 million at the start of the year.
See analysts’ growth forecasts and price targets for Mirum Pharmaceuticals stock (It’s free) >>>
What the Market Is Telling Us About Mirum Pharmaceuticals Stock
The reaction in Mirum Pharmaceuticals stock shows that investors are weighing near-term losses against a bigger growth story still playing out.
A widening loss combined with a revenue and guidance raise is a mixed signal, and it’s not unusual for biotech investors to focus first on the earnings miss even when the underlying business is clearly expanding.
Heading into this report, Mirum Pharmaceuticals stock had already climbed more than 20% for the year, more than the S&P 500’s gain. That kind of run-up can make a stock more sensitive to any disappointment, even one buried inside otherwise strong numbers.
Looking ahead, the company has several pipeline catalysts in the coming months, including a potential launch of zilurgisertib for FOP later this year and multiple late-stage trial readouts.
Wall Street’s consensus estimates currently call for continued losses next quarter and for the full year, but with a favorable trend in earnings estimate revisions heading into this report, some analysts still see room for Mirum Pharmaceuticals stock to outperform if the company’s growing drug portfolio and pipeline progress continue to deliver.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Mirum Pharmaceuticals Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
